BE904547A - NEW MEDICINES FOR TOPICAL USE. - Google Patents

NEW MEDICINES FOR TOPICAL USE.

Info

Publication number
BE904547A
BE904547A BE1/011467A BE1011467A BE904547A BE 904547 A BE904547 A BE 904547A BE 1/011467 A BE1/011467 A BE 1/011467A BE 1011467 A BE1011467 A BE 1011467A BE 904547 A BE904547 A BE 904547A
Authority
BE
Belgium
Prior art keywords
topical use
new medicines
salt
pharmacologically active
hyaluronic acid
Prior art date
Application number
BE1/011467A
Other languages
French (fr)
Original Assignee
Fidia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36694284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE904547(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from IT48980/85A external-priority patent/IT1184675B/en
Application filed by Fidia Spa filed Critical Fidia Spa
Publication of BE904547A publication Critical patent/BE904547A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates

Abstract

Préparations pharmaceutiques pour l'administration topique contenant une substance pharmacologiquement active en meme temps que de l'acide hyaluronique ou une des ses fractions moléculaires. L'acide hyaluronique peut exister sous la forme d'acide libre ou sous la forme de sel avec un métal alcalin ou alcalino-terreux, le magnésium, l'aluminiué ou l'ammonium ou sous la forme d'un sel avec une ou plusieurs substances pharmacologiquement actives.Pharmaceutical preparations for topical administration containing a pharmacologically active substance together with hyaluronic acid or one of its molecular fractions. Hyaluronic acid can exist in the form of free acid or in the form of salt with an alkali or alkaline earth metal, magnesium, aluminium or ammonium or in the form of a salt with one or more pharmacologically active substances.

BE1/011467A 1985-04-05 1986-04-03 NEW MEDICINES FOR TOPICAL USE. BE904547A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT8547924A IT1229075B (en) 1985-04-05 1985-04-05 Topical compsn. contg. hyaluronic acid deriv. as vehicle
CN85102921A CN85102921B (en) 1985-04-05 1985-04-09 Method of making pharmaceutical hyaluronic acid components and medical therefrom
IT48980/85A IT1184675B (en) 1985-12-23 1985-12-23 Topical compsn. contg. hyaluronic acid deriv. as vehicle

Publications (1)

Publication Number Publication Date
BE904547A true BE904547A (en) 1986-10-03

Family

ID=36694284

Family Applications (1)

Application Number Title Priority Date Filing Date
BE1/011467A BE904547A (en) 1985-04-05 1986-04-03 NEW MEDICINES FOR TOPICAL USE.

Country Status (27)

Country Link
US (1) US4736024A (en)
EP (2) EP0555898A3 (en)
JP (2) JP2585216B2 (en)
KR (1) KR910006810B1 (en)
CN (1) CN85102921B (en)
AR (1) AR245369A1 (en)
AT (1) ATE98495T1 (en)
AU (1) AU592077B2 (en)
BE (1) BE904547A (en)
CA (2) CA1340825C (en)
CH (1) CH672886A5 (en)
DE (1) DE3689384T3 (en)
DK (1) DK149886A (en)
ES (1) ES8800055A1 (en)
FI (1) FI83966C (en)
FR (1) FR2579895B1 (en)
HU (1) HU204202B (en)
IE (1) IE64440B1 (en)
IL (1) IL78263A0 (en)
IN (1) IN165867B (en)
IT (1) IT1229075B (en)
LU (1) LU86386A1 (en)
NO (1) NO174277C (en)
NZ (1) NZ215676A (en)
PH (1) PH29979A (en)
PT (1) PT82342B (en)
ZA (1) ZA862463B (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3806B (en) 1989-02-24 1996-03-25 Richter Gedeon Vegyeszet Hyaluronic acid associates, composition containing them, process for preparing the composition, process for preparing zinc hyaluronate aqueous solution
BG64458B1 (en) * 1997-04-29 2005-03-31 Richter Gedeon Vegyeszeti Gyar Rt. The use of zinc hyaluronate against peptic ulcer
EP2289522A1 (en) 2009-08-14 2011-03-02 Holy Stone Healthcare Co.,Ltd. Mixture of hyaluronic acid for treating and preventing peptic ulcer and duodenal ulcer
EP2292243A1 (en) 2009-08-14 2011-03-09 Holy Stone Healthcare Co.,Ltd. Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease
EP2543357A1 (en) 2011-07-07 2013-01-09 Holy Stone Healthcare Co.,Ltd. Composition for use in treating and preventing inflammation related disorder
EP2545925A1 (en) 2011-07-12 2013-01-16 Holy Stone Healthcare Co.,Ltd. Compositions comprising hyaluronic acid for treating and preventing mucosa related diseases
US8575130B2 (en) 2010-01-04 2013-11-05 Holy Stone Healthcare Co., Ltd. Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease
US8722644B2 (en) 2010-01-04 2014-05-13 Holy Stone Healthcare Co., Ltd. Mixture of hyaluronic acid for treating and preventing peptic ulcer and duodenal ulcer
US9029347B2 (en) 2010-08-05 2015-05-12 Holy Stone Healthcare Co., Ltd. Method and mixture for treating and preventing inflammatory bowel disease

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1186772B (en) * 1985-10-10 1987-12-16 Crinos Industria Farmaco COMPOUND WITH PILOSTIMULATING ACTIVITY
WO1987005517A1 (en) * 1986-03-14 1987-09-24 Bio-Technology General Corp. Heavy metal salts of hyaluronic acid useful as antimicrobial agents
ATE129254T1 (en) * 1987-03-19 1995-11-15 Arthropharm Pty Ltd ANTI-INFLAMMATORY AGENTS AND COMPOSITIONS.
US5668116A (en) * 1987-03-19 1997-09-16 Anthropharm Pty. Limited Anti-inflammatory compounds and compositions
ATE66133T1 (en) * 1987-05-20 1991-08-15 Ueno Seiyaku Oyo Kenkyujo Kk CONDOM.
AU621305B2 (en) * 1987-07-01 1992-03-12 Genentech Inc. Method and therapeutic compositions for the prevention of fibrin deposition or adhesions
US5055298A (en) * 1987-12-01 1991-10-08 Chemisches Laboratorium Dr. Kurt Richter Gmbh Cosmetic composition comprising an extracellular connective tissue matrix
JPH01213227A (en) * 1988-02-23 1989-08-28 Tadashi Koyake Ointment and solution
IT1219587B (en) * 1988-05-13 1990-05-18 Fidia Farmaceutici SELF-CROSS-LINKED CARBOXYLY POLYSACCHARIDES
US4981955A (en) * 1988-06-28 1991-01-01 Lopez Lorenzo L Depolymerization method of heparin
JPH0232013A (en) * 1988-07-20 1990-02-01 Denki Kagaku Kogyo Kk Nasal drop
JPH02200624A (en) * 1989-01-30 1990-08-08 Nippon Kayaku Co Ltd Dental dressing agent
US5472950A (en) * 1989-02-24 1995-12-05 Richter Gedeon Vegyeszeti Gyar Rt. Compositions containing cobalt hyaluronic acid complex
US6458774B1 (en) * 1989-02-24 2002-10-01 Richter Gedeon Vegyeszeti Gyar Rt. Compositions containing hyaluronic acid associates and a process for preparing same
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
JP2945993B2 (en) * 1989-12-05 1999-09-06 武田薬品工業株式会社 External preparation
US5141928B1 (en) * 1989-12-20 1995-11-14 Brujo Inc Ophthalmic medication
NL8903155A (en) * 1989-12-23 1991-07-16 Stamicarbon RESIN COMPOSITION BASED ON A POLYESTER RESIN, AN AMINO RESIN AND AN EPOXY RESIN.
ES2146200T3 (en) * 1990-02-13 2000-08-01 Ethicon Inc PERITONEALLY INDUCED DRUGS.
IT1240316B (en) * 1990-02-21 1993-12-07 Ricerca Di Schiena Del Dr. Michele G. Di Schiema & C. COMPOSITIONS BASED ON HIGH MOLECULAR WEIGHT HYLURONIC ACID ADMINISTRABLE BY TOPIC FOR THE TREATMENT OF INFLAMMATIONS OF THE ORAL CABLE, FOR COSMETICS AND HYGIENE OF THE ORAL CABLE
US5990096A (en) * 1990-09-18 1999-11-23 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US5639738A (en) * 1992-02-20 1997-06-17 Hyal Pharmaceutical Corporation Treatment of basal cell carcinoma and actinic keratosis employing hyaluronic acid and NSAIDs
CA2061566C (en) * 1992-02-20 2002-07-09 Rudolf E. Falk Treatment of disease employing hyaluronic acid and nsaids
US5824658A (en) * 1990-09-18 1998-10-20 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and NSAIDS
US5910489A (en) * 1990-09-18 1999-06-08 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and NSAIDS
CA2061703C (en) * 1992-02-20 2002-07-02 Rudolf E. Falk Formulations containing hyaluronic acid
IT1243435B (en) * 1990-10-05 1994-06-10 Altergon Sa PHARMACEUTICAL COMPOSITIONS FOR TOPICAL USE INCLUDING HYALURONIC ACID SODIUM SALT AND DISINFECTANT SUBSTANCES
US5492936A (en) * 1990-11-30 1996-02-20 Allergan, Inc. Bimodal molecular weight hyaluronate formulations and methods for using same
US5234914A (en) * 1991-06-11 1993-08-10 Patent Biopharmaceutics, Inc. Methods of treating hemorrhoids and anorecial disease
US5792753A (en) * 1991-07-03 1998-08-11 Hyal Pharmaceutical Corporation Compositions comprising hyaluronic acid and prostaglandin-synthesis-inhibiting drugs
WO1994007505A1 (en) * 1991-07-03 1994-04-14 Norpharmco Inc. Use of hyaluronic acid and forms to prevent arterial restenosis
US5817644A (en) * 1991-07-03 1998-10-06 Hyal Pharmaceutical Corporation Targeting of dosages of medicine and therapeutic agents
US5977088A (en) * 1991-07-03 1999-11-02 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US6103704A (en) * 1991-07-03 2000-08-15 Hyal Pharmaceutical Corporation Therapeutic methods using hyaluronic acid
US6022866A (en) * 1991-07-03 2000-02-08 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
US5990095A (en) * 1991-07-03 1999-11-23 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
US5834444A (en) * 1991-07-03 1998-11-10 Hyal Pharmaceutical Corporation Hyaluronic acid and salts thereof inhibit arterial restenosis
EP0625904B1 (en) * 1992-02-10 2003-05-28 Advanced Medical Optics, Inc. Bimodal molecular weight hyaluronate formulations and methods for using same
US6136793A (en) * 1992-02-20 2000-10-24 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US6218373B1 (en) 1992-02-20 2001-04-17 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
CA2061567C (en) * 1992-02-20 1998-02-03 Rudolf E. Falk Use of hyaluronic acid to repair ischemia reperfusion damage
US6114314A (en) * 1992-02-21 2000-09-05 Hyal Pharmaceutical Corp. Formulations containing hyaluronic acid
CA2130762C (en) * 1994-08-24 1999-07-06 Eva Anne Turley Treatment of disease and conditions associated with macrophage infiltration
US5767106A (en) * 1992-02-21 1998-06-16 Hyal Pharmaceutical Corporation Treatment of disease and conditions associated with macrophage infiltration
ES2079994B1 (en) * 1992-10-07 1996-08-01 Cusi Lab PHARMACEUTICAL FORMULATION BASED ON POLYMIXINE-TRIMETOPRIM AND AN ANTI-INFLAMMATORY AGENT FOR ITS TOPICAL OPHTHALMIC AND ETHICAL USE.
IT1263144B (en) * 1993-02-04 1996-08-01 Lanfranco Callegaro PHARMACEUTICAL COMPOSITIONS INCLUDING SPONGY MATERIAL CONSTITUTED FROM FOREIGN DERIVATIVES OF HYALURONIC ACID IN ASSOCIATION WITH OTHER PHARMACOLOGICALLY ACTIVE SUBSTANCES
IL108808A (en) * 1993-03-04 1996-09-12 Genzyme Ltd Controlled molecular weight reduction of polymers
US5616568A (en) * 1993-11-30 1997-04-01 The Research Foundation Of State University Of New York Functionalized derivatives of hyaluronic acid
JP4010574B2 (en) * 1994-12-05 2007-11-21 電気化学工業株式会社 Topical skin preparation
US5972326A (en) * 1995-04-18 1999-10-26 Galin; Miles A. Controlled release of pharmaceuticals in the anterior chamber of the eye
CA2154103C (en) * 1995-07-18 1998-02-24 Samuel Simon Asculai Treatment of mucous membrane disease, trauma or condition and for the relief of pain
ZA966579B (en) * 1995-08-04 1998-02-02 Wakamoto Pharma Co Ltd O/W emulsion composition for eye drops.
IT1287227B1 (en) 1996-04-04 1998-08-04 Fidia Spa In Amministrazione S HYALURONIC ACID AS A COMPONENT OF THE CORNEA PRESERVATION LIQUID
US5939047A (en) * 1996-04-16 1999-08-17 Jernberg; Gary R. Local delivery of chemotherapeutic agents for treatment of periodontal disease
US6451326B2 (en) 1996-05-02 2002-09-17 Burt D. Ensley Cosmetic compositions
IT1287967B1 (en) * 1996-10-17 1998-09-10 Fidia Spa In Amministrazione S PHARMACEUTICAL PREPARATIONS FOR LOCAL ANESTHETIC USE
US5843186A (en) * 1996-12-20 1998-12-01 Implemed, Inc. Intraocular lens with antimicrobial activity
US5789571A (en) * 1997-01-15 1998-08-04 Biocoat Incorporated Method of making free acids from polysaccharide salts
US20050090662A1 (en) * 1997-01-15 2005-04-28 Beavers Ellington M. Method of making free acids from polysaccharide salts
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
CA2285542C (en) * 1997-04-04 2007-07-17 Fidia Advanced Biopolymers Srl N-sulphated hyaluronic acid compounds, derivatives thereof and a process for their preparation
US6123957A (en) * 1997-07-16 2000-09-26 Jernberg; Gary R. Delivery of agents and method for regeneration of periodontal tissues
US6711436B1 (en) 1997-08-08 2004-03-23 Duke University Compositions, apparatus and methods for facilitating surgical procedures
US6060454A (en) * 1997-08-08 2000-05-09 Duke University Compositions, apparatus and methods for facilitating surgical procedures
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6426415B1 (en) 1997-09-03 2002-07-30 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6346536B1 (en) 1997-09-03 2002-02-12 Guilford Pharmaceuticals Inc. Poly(ADP-ribose) polymerase inhibitors and method for treating neural or cardiovascular tissue damage using the same
US6391336B1 (en) 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
US6395749B1 (en) 1998-05-15 2002-05-28 Guilford Pharmaceuticals Inc. Carboxamide compounds, methods, and compositions for inhibiting PARP activity
JP2002193830A (en) * 1998-10-19 2002-07-10 High Chem Co Ltd Medicinal preparation for nasal administration
DK172900B1 (en) * 1998-12-18 1999-09-27 Per Julius Nielsen Preparation and kit for use in intraocular surgery
US6387902B1 (en) 1998-12-31 2002-05-14 Guilford Pharmaceuticals, Inc. Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP
CN100374163C (en) 1999-01-13 2008-03-12 阿尔凯米亚肿瘤学私人有限公司 Composition and method for the enhancement of the efficacy of drugs
WO2000044367A2 (en) * 1999-02-01 2000-08-03 Dermal Research Laboratories, Inc. A pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
AU2001264595A1 (en) 2000-05-19 2001-12-03 Guilford Pharmaceuticals Inc. Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses
AU2001275085A1 (en) 2000-06-01 2001-12-11 Guilford Pharmaceuticals Inc. Methods, compounds and compositions for treating gout
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US6828308B2 (en) * 2000-07-28 2004-12-07 Sinclair Pharmaceuticals, Ltd. Compositions and methods for the treatment or prevention of inflammation
US7879824B2 (en) * 2001-07-31 2011-02-01 Dermal Research Laboratories, Inc. Methods of preventing or treating diseases and conditions using complex carbohydrates
US6726898B2 (en) 2000-11-17 2004-04-27 Gary R. Jernberg Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease
US6576226B1 (en) 2000-11-17 2003-06-10 Gary R. Jernberg Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease
DE60114229T2 (en) 2000-11-29 2006-07-06 Allergan, Inc., Irvine PREVENTING TRANSPLANT DISCHARGE IN THE EYE
ITMI20010708A1 (en) * 2001-04-03 2002-10-03 Alessandro Randazzo PHARMACOLOGICAL TREATMENT OF NIGHT BLINDS AND GHOST IMAGES WITH DILUTED PARASYMPATHOMYMETICS ACECLIDINE / PILOCARPINE AFTER INTER
AR034371A1 (en) * 2001-06-08 2004-02-18 Novartis Ag PHARMACEUTICAL COMPOSITIONS
JP2005505540A (en) * 2001-08-27 2005-02-24 メディテック　リサーチ　リミテッド Improved treatment protocol
HU229442B1 (en) * 2001-09-19 2013-12-30 Takeda Gmbh Combination of nsaid and pde-4 inhibitors and their use
ITMI20021666A1 (en) 2002-07-26 2004-01-26 Jasper Ltd Liability Co HYALURONIC ACID DERIVATIVES
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
WO2005016386A1 (en) * 2003-08-19 2005-02-24 Meditech Research Limited Improved therapeutic protocols
US20050043251A1 (en) * 2003-08-20 2005-02-24 Fairfield Clinical Trials, Llc Method of treatment of otitis externa
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US7625581B2 (en) * 2003-12-19 2009-12-01 Ethicon, Inc. Tissue scaffolds for use in muscoloskeletal repairs
US20050147570A1 (en) * 2004-01-06 2005-07-07 Nordsiek Michael T. Methods of administering diclofenac compositions for treating photodamaged skin, rosacea and/or acne
WO2005072701A1 (en) 2004-01-20 2005-08-11 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
FR2865651B1 (en) 2004-01-29 2007-09-28 Fabre Pierre Dermo Cosmetique TOPICAL COMPOSITIONS COMPRISING SODIUM HYALURONATE FRAGMENTS AND RETINOID USEFUL IN COSMETIC AND MEDICAL DERMATOLOGY
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
GB0416397D0 (en) * 2004-07-22 2004-08-25 Glaxo Group Ltd Pharmaceutical formulations
JP2008520546A (en) * 2004-09-21 2008-06-19 アドバンスト メディカル オプティクス， インコーポレーテッド Viscoelastic solution or gel formulation and method of treating a body part using the same
SE0402272D0 (en) 2004-09-21 2004-09-21 Amo Groningen Bv Methods of treating a body site with a viscoelastic preparation
EP1721602A1 (en) * 2005-05-11 2006-11-15 The Jordanian Pharmaceutical Manufacturing Co. Controlled release oral drug delivery system
FR2888752B1 (en) * 2005-07-22 2007-10-05 Fabre Pierre Dermo Cosmetique INTERMOLECULAR ASSOCIATION COMPLEX OF A CARRIER AND AN ACTIVE INGREDIENT
EP1912658B1 (en) * 2005-07-27 2017-01-25 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
JP5627181B2 (en) * 2005-09-07 2014-11-19 アルケミア オンコロジー ピーティーワイ リミテッド Therapeutic compositions comprising hyaluronan and therapeutic antibodies and methods of treatment
US20070065515A1 (en) * 2005-09-22 2007-03-22 Key Douglas J Methods and compositions for treating skin lines and wrinkles and improving skin quality
WO2010132402A1 (en) * 2009-05-11 2010-11-18 Morria Biopharmaceuticals, Inc Lipid-polymer conjugates, their preparation and uses thereof
JP4555232B2 (en) * 2006-01-25 2010-09-29 Ｈｏｙａ株式会社 Fluorescence staining method of tissue
US8668676B2 (en) 2006-06-19 2014-03-11 Allergan, Inc. Apparatus and methods for implanting particulate ocular implants
US8802128B2 (en) 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
CA2654255A1 (en) * 2006-06-28 2008-01-03 Novozymes Biopolymer A/S Compositions with several hyaluronic acid fractions for cosmetic and medical uses
WO2008003321A2 (en) * 2006-07-07 2008-01-10 Novozymes Biopolymer A/S Compositions with several hyaluronic acid fractions for cosmetic use
US20080097335A1 (en) 2006-08-04 2008-04-24 Allergan, Inc. Ocular implant delivery assemblies
CA2662581C (en) 2006-09-13 2018-01-30 Enhance Skin Products, Inc. Cosmetic composition for the treatment of skin and methods thereof
AU2008210557B2 (en) * 2007-01-30 2013-08-01 Cypress Pharmaceutical, Inc. Hyaluronate compositions
US20090068122A1 (en) * 2007-09-06 2009-03-12 Shira Pilch Dentifrice Compositions for Treating Xerostomia
KR101577471B1 (en) 2007-11-16 2015-12-14 알러간, 인코포레이티드 Compositions and methods for treating purpura
US20090306025A1 (en) * 2008-05-30 2009-12-10 Fairfield Clinical Trials, Llc Method and composition for skin inflammation and discoloration
WO2010003797A1 (en) * 2008-07-09 2010-01-14 Novozymes Biopharma Dk A/S Hyaluronic acid for corneal wound healing
EP2337536B1 (en) 2008-10-02 2020-08-12 L.R. R & D Ltd. Interface layer wound dressing
CN101385874B (en) * 2008-10-23 2012-11-28 武汉大学 Preparation method of biology synovial fluid containing polymer hyaluronic acid
US8545554B2 (en) 2009-01-16 2013-10-01 Allergan, Inc. Intraocular injector
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
US20110172180A1 (en) 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
IT1407283B1 (en) * 2010-12-06 2014-04-04 Paoli Ambrosi De NEW COMPOUND OF CARNOSINE
CZ303548B6 (en) 2011-01-05 2012-11-28 Contipro Pharma A.S. Iodine-forming health formulation, process of its preparation and bandage containing thereof
CZ22394U1 (en) 2011-03-11 2011-06-20 Contipro C, A.S. Antimicrobial mixture and cover to support healing of wounds with antimicrobial effect
ITMI20111747A1 (en) 2011-09-28 2013-03-29 Fidia Farmaceutici TOPICAL PHARMACEUTICAL COMPOSITIONS INCLUDING ACICLOVIR
ITPD20120173A1 (en) 2012-05-31 2013-12-01 Fidia Farmaceutici "NEW HYDROPHOBIC PROTEIN RELEASE SYSTEM"
JP2014141475A (en) * 2012-12-27 2014-08-07 Daiichi Sankyo Co Ltd Novel skin-whitening agent
KR101412776B1 (en) 2013-03-11 2014-07-01 가톨릭대학교 산학협력단 Eye drop composition for treating keratoconjunctivitis and preparation method of the same
CN103319627A (en) * 2013-07-10 2013-09-25 南宁中诺生物工程有限责任公司 Method for grading molecule weight of sodium hyaluronate
US9089562B2 (en) * 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US20170007637A1 (en) * 2014-02-11 2017-01-12 Orasis Pharmaceuticals Ltd. Pharmacological ophthalmic composition for use in the correction of presbyopia and its administration
EP2910255A1 (en) * 2014-02-19 2015-08-26 MedSkin Solutions Dr. Suwelack AG Methods for the production of biopolymers with defined average molecular weight
US9603867B2 (en) * 2015-03-03 2017-03-28 Yung Shin Pharm. Ind. Co., Ltd. Pharmaceutical composition for improving wound healing or prophylactically preventing or inhibiting scar formation
ITUB20152542A1 (en) * 2015-07-28 2017-01-28 Altergon Sa OPHTHALMIC FORMULATIONS BASED ON COOPERATIVE COMPLEXES OF HYALURONIC ACID LOW AND HIGH MOLECULAR WEIGHT
EP4166145A1 (en) 2016-02-12 2023-04-19 Laimu Corporation Nerve growth promoter and method for producing same, internal preparation, medium additive, cell dilution additive, medium, cell dilution, antioxidant and method for producing same, external preparation, and wound treatment agent and method for producing same
ES2934790T3 (en) 2016-08-19 2023-02-27 Orasis Pharmaceuticals Ltd Ophthalmic pharmaceutical compositions and uses related thereto
CN106727246A (en) * 2017-02-08 2017-05-31 上海元茵生物科技有限公司 Calf serum cell nutrient solution
CN107802597B (en) * 2017-12-08 2020-07-31 北京诺康达医药科技股份有限公司 Sodium hyaluronate composition and preparation method and application thereof
EP3740191B1 (en) * 2018-01-18 2021-04-28 Faes Farma, S.A. Ophthalmic compositions comprising bilastine, a beta-cyclodextrin and at least one gelling agent
FR3086865B1 (en) * 2018-10-04 2023-04-28 Matthieu Leconte OPHTHALMIC PREPARATION AND ORTHOKERATOLOGY LENS FOR THE INHIBITION, PREVENTION AND/OR LIMITATION OF THE PROGRESSION OF MYOPIA

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2583096A (en) * 1949-01-15 1952-01-22 Searle & Co Process for the production of high viscosity hyaluronic acid
DE1047380B (en) * 1954-08-18 1958-12-24 American Home Prod Process for the production of a hyaluronidase-free, partially depolymerized hyaluronic acid containing aqueous carrier solution for pharmaceuticals
GB818336A (en) * 1956-06-22 1959-08-12 Erba Carlo Spa A new acid aminopolysaccharide and a process for the production thereof
FR1425265A (en) * 1962-05-14 1966-01-24 Parke Davis & Co Process for the preparation of a new polysaccharide and its salts
FR3715M (en) * 1964-06-11 1965-11-29 Lucien Nouvel Improved antithermics and antirheumatic drugs.
US3887703A (en) * 1967-03-24 1975-06-03 Oreal Mucopolysaccharides, their preparation and use in cosmetic and pharmaceutical compositions
US3792164A (en) * 1970-03-31 1974-02-12 Chemway Corp Ophthalmic composition comprising water-soluble alkaloid salts of polyuronic acids
GB1283892A (en) * 1970-06-08 1972-08-02 Irwin Irville Lubowe Improvements in and relating to medicinal compositions for application to the skin and/or hair
DE2364373A1 (en) * 1973-12-22 1975-07-10 Hahn Carl Dr Gmbh Pharmaceutical and/or cosmetic prepns. - contg. methyl-substd. xanthine, oestriol and/or a mucopolysaccharide
US3936081A (en) * 1974-02-27 1976-02-03 R & G Sloane Manufacturing Co., Inc. Pipe joint and method of making same
US4141973A (en) * 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
HU172937B (en) * 1975-12-18 1979-01-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing chondroitinsulphuric acid derivatives with local anaesthetic activity
SE7901565L (en) * 1979-02-21 1980-08-22 Pharmacia Ab Means of Immunization
JPS55153711A (en) * 1979-05-19 1980-11-29 Pola Chem Ind Inc Cosmetic lotion
HU185926B (en) * 1979-09-27 1985-04-28 Agostne Kahan Process for preparing water soluble derivatives of non-steroid antiinflammatory compositions and pharmaceutical compositins containing such derivatives
US4272522A (en) * 1979-10-15 1981-06-09 Balazs Endre A Method for stimulating phagocytic activity and synergistic compositions therefor
US4303676A (en) * 1980-03-21 1981-12-01 Balazs Endre A Hyaluronate based compositions and cosmetic formulations containing same
JPS5885813A (en) * 1981-11-17 1983-05-23 Toyo Jozo Co Ltd Drug preparation having high absorbability
JPS57183707A (en) * 1981-05-02 1982-11-12 Shiseido Co Ltd Cosmetic
US4359458A (en) * 1981-09-28 1982-11-16 American Cyanamid Company O-β. -D (and O-α.. -D) Multigalactopyranosyl, xylopyranosyl and glucopyranosyl sulfate salts
JPS591405A (en) * 1982-06-28 1984-01-06 Shiseido Co Ltd Emulsifiable composition
JPS597106A (en) * 1982-07-06 1984-01-14 Shiseido Co Ltd Emulsifiable composition
JPS5920212A (en) * 1982-07-27 1984-02-01 Shiseido Co Ltd Emulsified composition
JPS5939338A (en) * 1982-08-30 1984-03-03 Shiseido Co Ltd Emulsified composition
IT1212892B (en) * 1983-10-11 1989-11-30 Della Valle Francesco HYALURONIC ACID OBTAINED BY MEANS OF MOLECULAR FILTRATION WITHOUT INFLAMMATORY ACTIVITY AND ITS THERAPEUTIC USE
JPS59219209A (en) * 1983-05-28 1984-12-10 Kanebo Ltd Skin cosmetic
AU555747B2 (en) * 1983-08-09 1986-10-09 Cilco Inc. Chondroitin sulfate and sodium hyaluronate composition
EP0138752B1 (en) * 1983-08-12 1986-11-12 Ciba-Geigy Ag Monoclinic lead chromate pigments
DE3334595A1 (en) * 1983-09-24 1985-04-18 B. Braun Melsungen Ag, 3508 Melsungen ACTIVE SUBSTANCE DEPOSIT
LU85582A1 (en) * 1983-10-11 1985-06-04 Fidia Spa HYALURONIC ACID FRACTIONS HAVING PHARMACEUTICAL ACTIVITY, METHODS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
JPS61180723A (en) * 1985-02-06 1986-08-13 Sanwa Kagaku Kenkyusho:Kk Composition for formulating easily absorbable kallidinogenase
US5095037B1 (en) * 1989-12-21 1995-12-19 Nissho Kk Combined anti-inflammatory agent
ES2146200T3 (en) * 1990-02-13 2000-08-01 Ethicon Inc PERITONEALLY INDUCED DRUGS.

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3806B (en) 1989-02-24 1996-03-25 Richter Gedeon Vegyeszet Hyaluronic acid associates, composition containing them, process for preparing the composition, process for preparing zinc hyaluronate aqueous solution
BG64458B1 (en) * 1997-04-29 2005-03-31 Richter Gedeon Vegyeszeti Gyar Rt. The use of zinc hyaluronate against peptic ulcer
EP2289522A1 (en) 2009-08-14 2011-03-02 Holy Stone Healthcare Co.,Ltd. Mixture of hyaluronic acid for treating and preventing peptic ulcer and duodenal ulcer
EP2292243A1 (en) 2009-08-14 2011-03-09 Holy Stone Healthcare Co.,Ltd. Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease
EP3842046A1 (en) 2009-08-14 2021-06-30 Holy Stone Healthcare Co.,Ltd. Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease
US8575130B2 (en) 2010-01-04 2013-11-05 Holy Stone Healthcare Co., Ltd. Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease
US8722644B2 (en) 2010-01-04 2014-05-13 Holy Stone Healthcare Co., Ltd. Mixture of hyaluronic acid for treating and preventing peptic ulcer and duodenal ulcer
US9029347B2 (en) 2010-08-05 2015-05-12 Holy Stone Healthcare Co., Ltd. Method and mixture for treating and preventing inflammatory bowel disease
EP2543357A1 (en) 2011-07-07 2013-01-09 Holy Stone Healthcare Co.,Ltd. Composition for use in treating and preventing inflammation related disorder
EP2545925A1 (en) 2011-07-12 2013-01-16 Holy Stone Healthcare Co.,Ltd. Compositions comprising hyaluronic acid for treating and preventing mucosa related diseases
US10709731B2 (en) 2011-07-12 2020-07-14 Aihol Corporation Materials for treating and preventing mucosa related disease

Also Published As

Publication number Publication date
ES8800055A1 (en) 1987-11-16
CH672886A5 (en) 1990-01-15
AR245369A1 (en) 1994-01-31
EP0197718A2 (en) 1986-10-15
ZA862463B (en) 1987-12-30
IN165867B (en) 1990-02-03
IT8547924A0 (en) 1985-04-05
LU86386A1 (en) 1986-09-02
IE64440B1 (en) 1995-08-09
NZ215676A (en) 1989-08-29
EP0197718B2 (en) 2001-07-25
AU5566286A (en) 1986-10-16
FI83966C (en) 1991-09-25
NO861331L (en) 1986-10-06
CN85102921A (en) 1986-10-08
IL78263A0 (en) 1986-07-31
NO174277B (en) 1994-01-03
FR2579895B1 (en) 1990-11-23
DK149886D0 (en) 1986-04-02
IE860847L (en) 1986-10-05
PT82342A (en) 1986-05-01
KR910006810B1 (en) 1991-09-02
HU204202B (en) 1991-12-30
JP2585216B2 (en) 1997-02-26
EP0555898A3 (en) 1993-10-20
DK149886A (en) 1986-10-06
CA1340825C (en) 1999-11-23
CA1341418C (en) 2003-01-21
EP0197718A3 (en) 1987-09-09
US4736024A (en) 1988-04-05
ATE98495T1 (en) 1994-01-15
FI861395A (en) 1986-10-06
CN85102921B (en) 1988-06-08
AU592077B2 (en) 1990-01-04
KR860008202A (en) 1986-11-12
PH29979A (en) 1996-10-29
HUT40579A (en) 1987-01-28
FI83966B (en) 1991-06-14
NO174277C (en) 1994-04-13
DE3689384T2 (en) 1994-07-07
ES553714A0 (en) 1987-11-16
DE3689384T3 (en) 2003-05-15
EP0197718B1 (en) 1993-12-15
FR2579895A1 (en) 1986-10-10
PT82342B (en) 1988-03-03
JP2677778B2 (en) 1997-11-17
FI861395A0 (en) 1986-04-01
IT1229075B (en) 1991-07-17
EP0555898A2 (en) 1993-08-18
JPH09169667A (en) 1997-06-30
JPS61236732A (en) 1986-10-22
DE3689384D1 (en) 1994-01-27

Similar Documents

Publication Publication Date Title
BE904547A (en) NEW MEDICINES FOR TOPICAL USE.
MA21264A1 (en) COMPOSITION FOR ADMINISTERING MEDICAMENT IN THE FORM OF CELLS, POWDER OR LIQUID.
FR2598319B1 (en) DOSAGE FORM FOR DELIVERY OF A MEDICINAL COMPOSITION TO A MEDIA FOR USE
BE1002159A5 (en) MEDICINAL ADSORBATES.
FR2784294B1 (en) COSMETIC AND / OR DERMATOLOGICAL COMPOSITION CONTAINING AT LEAST ONE WALL EXTRACT, AT LEAST ONE SCUTELLAR EXTRACT AND AT LEAST ONE SALICYLIC ACID DERIVATIVE
AR028299A1 (en) A PHARMACEUTICAL COMPOSITION THAT INCLUDES NATEGLINIDA, A PROCESS FOR ITS PREPARATION AND THE USE OF SUCH COMPOSITION FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF METABOLIC DISORDERS, ESPECIALLY DIABETES, OR A DISEASE OR CONDITION ASSOCIATED WITH DIABETY.
CA2246289A1 (en) New associations of active principles containing clopidogrel and an antithrombotic agent
IT8621358A0 (en) PHARMACEUTICAL COMPOSITION ANALGESIC ADAPTIVITY.
FR2719999B1 (en) Pharmaceutical composition based on guar gum and a neutralizing antacid, to which can be added a series of therapeutic active ingredients.
BE873843A (en) BASIC ALUMINUM AND MAGNESIUM CARBONATE, ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS IN CONTAINING
FR2774687B1 (en) LIPOPEPTIDES CONTAINING A FRAGMENT OF THE INTERFERON GAMMA, AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS
BE1002665A4 (en) NOVEL CRYSTALLINE FORM OF CICLOSPORIN, ITS PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT.
KR860002525A (en) Giant wall pills
FR2598320B1 (en) WATER-SOLUBLE PHARMACEUTICAL COMPOSITIONS CONTAINING UBIQUINONE AS ACTIVE INGREDIENT USEFUL IN DIFFERENT THERAPEUTIC APPLICATIONS
CA2235038A1 (en) Use of a tnf alpha antagonist for treating neurogenic skin redness
BG104527A (en) Formulations comprising dissolved paroxetine
KR910009267A (en) How to Treat Depression
BE1002182A5 (en) PHARMACEUTICAL COMPOSITIONS.
TNSN99190A1 (en) LIQUID CONCENTRATED PHARMACEUTICAL COMPOSITION OF SERTRALINE AND PROCESS FOR ITS PREPARATION
IT8722031A0 (en) PHARMACEUTICAL FORMULATIONS AND DOSAGE FORMS FOR THE RECTAL ADMINISTRATION OF CALCITONIN.
BE902055A (en) PHARMACEUTICAL PREPARATIONS.
BE901963A (en) DOSED FORM OF ETOPOSIDE FOR ORAL USE.
KR880002535A (en) Use of 15-deoxyspergualin as a medicament
FR2515516B1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INFECTED RENAL LITHIASIS CONTAINING PROPIONOHYDROXAMIC ACID OR ITS PHARMACY ACCEPTABLE SALTS
RU2001120110A (en) PHARMACEUTICAL MIXTURE PROFEN

Legal Events

Date Code Title Description
RE20 Patent expired

Owner name: *FIDIA S.P.A.

Effective date: 20060403